Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
December 08, 2021 07:00 ET
|
Ikena Oncology, Inc.
Dr. Zhang steps into the CSO role after spending more than five years at Ikena in research and development leadership Jeffrey Ecsedy, Ph.D., taking on newly created role as Chief Development...
Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175
November 12, 2021 07:00 ET
|
Ikena Oncology, Inc.
Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors Study evaluates IK-175 in urothelial carcinoma...
Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update
November 10, 2021 07:00 ET
|
Ikena Oncology, Inc.
IND for IK-930 accepted by FDA; Phase 1 clinical trial expected to initiate in early 2022 Progressing RAS pathway research programs with multiple development candidates expected in the next 18 months...
Ikena Oncology to Participate in November 2021 Virtual Investor Conferences
November 04, 2021 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced...
Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
November 02, 2021 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced today...
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
October 07, 2021 09:00 ET
|
Ikena Oncology, Inc.
Meeting, taking place October 7-10, 2021, is hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment...
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
October 01, 2021 08:15 ET
|
Ikena Oncology, Inc.
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three...
Ikena Oncology to Participate in September 2021 Virtual Investor Conferences
September 02, 2021 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today...
Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs
August 12, 2021 07:00 ET
|
Ikena Oncology, Inc.
IK-930 IND on track for submission in 2021; multiple upcoming preclinical and translational conference presentations on TEAD inhibition by IK-930 Progressing IK-175 clinical trial monotherapy...
Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021
July 08, 2021 07:00 ET
|
Ikena Oncology, Inc.
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation...